

**Task History**

June 27, 2011 3:41 PM

**Explore references by research topic: imiquimod treating wrinkles initiated, resulting in 1 candidate**

**Explore complete**

**Candidates Selected**

18 references were found containing all of the concepts "imiquimod", "treating" and "wrinkles".

**Explore results**

~~Answer set 2~~ created with

17 answers from CAPLUS

1 answer from MEDLINE

**1. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof**

By Tamarkin, Dov; Schuz, David; Berman, Tal; Hazot, Yohan

From PCT Int. Appl. (2010), WO 2010125470 A2 20101104. Language: English, Database: CAPLUS

The present invention relates to a foamable pharmaceutical and cosmetic compns. and foams comprising an aprotic polar solvent and uses thereof. Thus, a waterless foamable compns. comprising DMSO, glycerol monostearate and AP-70 propellant was prepd. having excellent foam quality and collapse time of > 180 s. The addn. of various drugs (diclofenac, minocycline HCl or terbinafine) gave good quality breakable foams which did not collapse after 180 s of incubation at 36°. Microscopic observation of foam samples revealed the drugs were dissolved in these formulations. The drug bioavailability should be improved if dissolved since the DMSO can then aid penetration.

**~0 Citings****0 Tags****0 Comments**

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**2. Oil-based foamable pharmaceutical carriers and formulations**

By Tamarkin, Dov; Schuz, David; Hazot, Yohan; Gazal, Elena

From PCT Int. Appl. (2010), WO 2010041141 A2 20100415. Language: English, Database: CAPLUS

The present invention relates to a waterless foamable carrier and pharmaceutical compn. which is suitable for external and internal administration. The compn. is single phase and includes at least one liq. oil; and a glyceride. Pharmaceutical compns. comprising active agents, methods for their prepn., propellants suitable for use with the carriers and uses thereof are further described.

**~0 Citings****0 Tags****0 Comments**

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**3. Formulation based on micronized clinoptilolite as therapeutic agent providing highly bioavailable silicon**

By Lelas, Antonio; Cepanac, Ivaca

From PCT Int. Appl. (2010), WO 2010016418 A1 20100218. Language: English, Database: CAPLUS

This invention relates to a formulation based on micronized clinoptilolite (MC) as therapeutic agent for effective release of highly bioavailable silicon. The formulation comprises variable portions of: (i) micronized clinoptilolite (MC) of general formula:  $(\text{Men}^+)_x / n[(\text{AlO}_2)_x(\text{SiO}_2)_y] \cdot m\text{H}_2\text{O}$  (MC) where Me = H, Li, Na, K, Mg, Ca, Zn, Ag, Cu, Mn, Fe; whereas ratio of silicon to aluminum, y:x is between 2.6:1 to 5:1; no. of cryst. water m is 0-20, which is characterized by particles size from 500 nm to 5 µm; and of (ii) one or more excipients which yield in desired pharmaceutical form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liq. powders, compact powders, masks, suppositories, syrups, suspensions, soaps, and therapeutic patches; and of one or more pharmaceutical or cosmetic active substances which contribute and/or enhance basic biol. actions of silicic acid. The use of the formulation provides all known pos. therapeutic effects of highly bioavailable silicon: stimulation of immune system; **treatment** of allergic conditions; adjuvant therapy at microbial infections; increasing strength of blood vessel walls, and decreasing of their wall permeability; stimulation of joint and ligament functions; stimulation of osteoblasts and bone mineralizations; prevention of osteoporosis; decreasing resorption of aluminum from gastrointestinal tract; improving structure of cartilage; antiinflammatory action at various acute or chronic inflammatory diseases; **treatment** of various skin diseases such as skin irritations, eczema, seborrheic dermatitis, neurodermatitis, atopic dermatitis, psoriasis; **treatment** of decubitus; **treatment** of wounds and burns; stimulation of biosynthesis of collagen and elastin; slowing down of skin aging; redn. of **wrinkles**; stimulation of hair growth, strength, and brightness; and stimulation of nail growth and strength. Pure micronized calcium clinoptilolite (Ca-MC;  $\text{CaAl}_2\text{Si}_7\text{O}_{18}$ ) was prepd. from natural clinoptilolite and formulated into tablets.

**~0 Citings****0 Tags****0 Comments**

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**4. Combination therapies for ~~treating~~ photodamaged skin**

By Baumann, Leslie

From U.S. Pat. Appl. Publ. (2009), US 20090232755 A1 20090917. Language: English, Database: CAPLUS

Combination therapies for reducing the appearance of fine lines and **wrinkles** on aged skin or non-precancerous, normal photodamaged section of skin, in a patient not being **treated** for viral infection or skin cancer comprising (i) topical application of an imidazoquinolinamine deriv. in a dermatol.-acceptable carrier in further combination with one or more cosmetic **treatments** selected from the group consisting of: (i) Light Emitting Diode (L.E.D.) Light Therapy; (ii) Intense Pulsed Light (I.P.L.) Therapy; (iii) laser skin resurfacing; (iv) mech. exfoliation; (v) superficial, medium depth or deep chem. peels; (vi) radiofrequency **treatment**; (vii) ultrasound **treatment**; (viii) intradermal and intraepidermal injections with hyaluronic acid and derivs. thereof; and (ix) cryosurgery. Thus, a gel contg. Carbomer 0.5, **imiquimod** 5.0, Helianthus annuus (sunflower) seed ext. 1.0, panthenol 1.0, Aloe vera 1.0, preservative 1.0, and water 90.5%, resp., was exemplified.

**~0 Citings**

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**5. Methods and compositions for treating skin conditions by inducing reepithelialization of skin**

By Pojasek, Kevin; Steinberg, David; Zohar, Daphne

From PCT Int. Appl. (2008), WO 2008143928 A1 20081127. Language: English, Database: CAPLUS

The invention features methods, kits, and compns. for **treating** aging- related skin conditions (e.g., **wrinkles**), pigmentation disorders, acne, and scar formation, as well as methods, kits, and compns. for preventing scar formation by inducing reepithelialization of the skin. The therapeutic compd. selected to improve an aging related skin condition can be a compds. that modulate the retinoic acid signaling pathway (such as trans-retinoic acid, N-retinoyl-D-glucosamine, and seletinoid G), the estrogen signaling pathway (e.g., 17 $\beta$ -estradiol and selective estrogen receptor modulators), the ubiquitin-proteasome system, or a cytokine signaling (e.g., **Imiquimod** and interleukin- $\alpha$ ). The therapeutic compd. can also be a cell (e.g., a cell capable of inducing differentiation of an uncommitted epidermal cell and a cell capable of differentiating into an epidermal cell).

~0 Citings

0 Tags

0 Comments


Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**6. 2,5-dihydroxybenzene derivatives for treating actinic keratosis**

By Cuevas Sanchez, Pedro; Gimenez Gallego, Guillermo; Saenz De Tejada Morgan, Inigo; Angulo Frutos, Javier; Valverde Lopez, Serafin; Romero Garrido, Antonio; Lozano Puerto, Rosa Maria

From U.S. Pat. Appl. Publ. (2008), US 20080126485 A1 20080529. Language: English, Database: CAPLUS

The invention relates to the use of a 2,5-dihydroxybenzene deriv. (I) [R<sup>1</sup> = (CH<sub>2</sub>)<sub>a</sub>Y, CH=CH(CH<sub>2</sub>)<sub>p</sub>Y; a, p = 0-6; Y = SO<sub>3</sub>H, CO<sub>2</sub>H, etc.; R<sub>9</sub>, R<sub>9</sub>' = (un)substituted OH], or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof, for the therapeutic and /or prophylactic **treatment** of, inter alia, actinic keratosis.



~0 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**7. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof for treatment of skin and other disorders**

By Tamarkin, Doy; Friedman, Doron; Eini, Meir; Berman, Tal; Schuz, David

From U.S. Pat. Appl. Publ. (2005), US 20080069779 A1 20080320. Language: English, Database: CAPLUS

Vitamin and flavonoid contg. compns. are provided that are stable to degradn. Stabilized compns. include one or more features including a hygroscopic solvent at a sufficient concn. to provide an Aw value of the hygroscopic vitamin and or flavonoid contg. compn. of less than 0.9, antioxidant flavonoids that are preferentially oxidized before the vitamin, preservatives, and hydrocarbon propellants selected to reduce the oxidn. potential of the compn. Thus, a foamable carrier was prepd. contg. propylene glycol 88.00, stearyl alc. 2.00, hydroxypropyl cellulose 2.00, Laureth-4 2.00, GMS NE 2.00, macrogol cetostearyl ether 1.00, and PPG-15 stearyl ether 3.00%, resp. Ascorbic acid and niacinamide were concurrently added to the carrier at 5.00% and 2.00%, resp. Following addn. of a propellant, the foamable compn. was obtained, which upon release from an aerosol pressurized container afforded foam of good quality. The foam was easily spread and immediately absorbed into the facial skin with no extensive rubbing.

~6 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**8. Composition and method for topical treatment of tar-responsive dermatological disorders**

By Yu, Ruey J.; Van Scott, Eugene J.; Lee, Yaling

From U.S. Pat. Appl. Publ. (2007), US 20070207222 A1 20070906. Language: English, Database: CAPLUS

The present invention relates to a compn. including a wax and a therapeutically effective amt. of tar for topical **treatment** of a tar-responsive dermatol. disorder, the compn. being in liq. or light gel form when at a temp. selected from room temp. and a temp. of skin of a mammal upon application of the compn. to the skin of the mammal. The invention also relates to a method of **treating** a tar-responsive dermatol. disorder by topically applying the compn. to skin of a mammal, preferably a human, that is affected by the disorder. Thus, a fast-drying liq. tar compn. was formulated contg. coal tar soln. 15 g, ethanol 42 g, propylene glycol 5 g,

cyclomethicone (DC 345) 15 g, tri-Et citrate 5 g, Brij 93 10 g, liq. wax DIADD (dioctyldodecyl dodecanedioate) 5 g, and an optional fragrance 3 g. Topical application of the compn. for 4 mo to a human subject having plaque psoriasis resulted in 90% improvement of clin. signs of disorder.

~1 Citing

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

9. **Fragranced therapeutic delivery system comprising phenoxyethanol and exfoliating hydroxycarboxylic acids**

By Murad, Howard; Akyuz, Fatma

From PCT Int. Appl. (2007), WO 2007092085 A2 20070816. Language: English, Database: CAPLUS

The present invention relates to multifunctional topical delivery systems for providing long-lasting delivery of fragrance as well as skin-supporting and/or pharmaceutically active ingredients comprising (i) an oil phase, (ii) an aq. phase, (iii) phenoxyethanol at a concn. of about 2.0% to about 2.7% based on the total wt. of the compn., (iv) an effective exfoliating amt. of a hydrophobic hydroxycarboxylic acid selected from the group consisting of o-hydroxybenzoic acid, hydroxycarboxylic acids contg. a C12-24 fatty acid esterified to the alpha carbon hydroxyl group, hydroxycarboxylic acids contg. a C12-24 fatty alc. esterified to a carboxyl group, (v) a nonionic emulsifier having an HLB of about 7 to about 10, (vi) a fragrance compn., and (vii) at least one skin-supporting or dermatopharmaceutically active agent. Thus, an extended fragrance delivery vehicle contained water 69.14, Pemulen TR-1 0.18, Dissolvine 220 0.05, aminomethylpropanol 0.90, phenoxyethanol 2.70, salicylic acid 0.50, Hetester PHA 2.00, Beantree 2.00, Bernel Ester CO 1.00, Simulsol 165 0.01, mango butter 0.01, olive butter, vitamin E acetate, SD Alc. 40-B 20.00, and essential oil blend 0.50 parts, resp.

~2 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

10. **Film forming foamable pharmaceutical and cosmetic compositions and cosmetic and therapeutic uses thereof**

By Tamarkin, Dov; Friedman, Doron; Eini, Meir

From U.S. Pat. Appl. Publ. (2006), US 20060193759 A1 20060831. Language: English, Database: CAPLUS

The present invention provides a film-forming foamable cosmetic or pharmaceutical vehicle, and cosmetic and/or pharmaceutical compns. thereof. Specifically, the foamable compn., includes (1) about 6% to about 70% by wt. of at least one org. carrier; (2) about 0.1 % to about 5% by wt. of at least one surface-active agent; (3) about 0.01% to about 5% by wt. of at least one film forming agent; (4) water; and (5) about 3% to about 25% by wt. of the total compn. of at least one liquefied or compressed gas propellant. The compn. is substantially alc. free and is used in **treating**, alleviating or preventing a disorder.

~4 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

11. **Pharmaceutical compositions comprising o-acetylsalicyl derivatives of amino saccharides and amino acids**

By Yu, Ruey J.; Van Scott, Eugene J.

From PCT Int. Appl. (2006), WO 2006074114 A2 20060719. Language: English, Database: CAPLUS

The embodiments described herein include a compn. and method of **treatment** using compns. that include at least 1 acetylsalicyl deriv. The compns. and methods are useful in preventing and **treating** disorders and syndromes assocd. with anyone of the nervous, vascular, musculoskeletal, or cutaneous systems. N-(O-acetylsalicyl)-D-galactosamine 5 g was dissolved in warm propylene glycol 35 mL, and the soln. thus obtained was mixed with hydrophilic ointment or oil-in-water cream (60 g). The cream thus prepd. had pH 3.9 and contained 5% N-(O-acetylsalicyl)-D-galactosamine.

~6 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

12. **Acidic drug complexes for improved bioavailability and delivery**

By Yu, Ruey J.; Van Scott, Eugene J.

From PCT Int. Appl. (2004), WO 2004082628 A2 20040906. Language: English, Database: CAPLUS

Embodiments of the invention relate to a compn., a process of making the compn., and to the use of the compn. The compns. include a mol. complex formed between an acidic pharmaceutical drug and at least one functional substance. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, methotrexate complex with L-lysine was found to have less skin irritation when applying topically to **treat** psoriasis on the forearm.

~6 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**13. Improved bioavailability and improved delivery of alkaline drugs**

By Yu, Ruey J.; Van Scott, Eugene J.

From PCT Int. Appl. (2004), WO 2004080468 A1 20040925. Language: English, Database: CAPLUS

Embodiments of the invention relate to a compn., a process of making the compn., and to the use of the compn. The compns. include a mol. complex formed between an alk. pharmaceutical and at least one selected from a hydroxyacid, a polyhydroxy acid, a related acid, a lactone, or combinations thereof. The compns. provide improved bioavailability and improved delivery of the drug into the cutaneous tissues. For example, diphenhydramine hydrochloride 29 g (0.1 mol) was dissolved in water (50 mL) and 5N sodium hydroxide (20 mL) was slowly added to generate diphenhydramine as a free base as shown by the formation of oily ppts. and the change from pH 5.5 to 9.4. Gluconolactone 18 g (0.1 mol) was added to form a mol. complex between the diphenhydramine free base and gluconic acid /gluconolactone as shown by the disappearance of the oily ppts. and the change from pH 9.4 to 7.4. The soln. thus obtained contained 0.1 mol diphenhydramine in mol. complex with 0.1 mol gluconic acid /gluconolactone. This concd. stock soln. was used for various forms of topical formulations including oil-in-water creams, lotions, gels and solns.

~1 Citing

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**14. Methods of improving skin quality using topical TLR agonists**

By Miller, Richard L.; Lee, James H.; Owens, Mary L.

From U.S. Pat. Appl. Publ. (2004), US 20040190919 A1 20040916. Language: English, Database: CAPLUS

Methods of improving skin quality are disclosed. Generally, the methods include topically administering an immune response modifier (IRM) compd. to a **treatment** area of skin for a period of time and in an amt. effective for improving the quality of the skin. Suitable IRM compds. include agonists of one or more toll-like receptor (TLR), such as an imidazoquinoline amine, an imidazopyridine amine, a 6,7-fused cycloalkylimidazopyridineamine, an imidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinolineamine, an oxazolopyridine amine, a thiazolopyridineamine, an oxazolophthyridine amine, a thiazolophthyridineamine, or their combination. For example, subjects having cutaneous leishmaniasis received, in addn. to the std. care for leishmaniasis (meglumine antimonate, 20 mg/Kg) for 20 consecutive days, either 5% **imiquimod** cream (Aldara) or a placebo cream. An improvement in quality of the skin was obsd. in subjects receiving **imiquimod** during the **treatment** period.

~1 Citing

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**15. Urea compositions for the treatment of skin disorders**

By Yu, Ruey J.; Van Scott, Eugene J.

From PCT Int. Appl. (2003), WO 2003086291 A2 20031023. Language: English, Database: CAPLUS

The invention is directed to compns., methods of making the compns., and methods of **treating** cosmetic and dermatol. disorders with a compn. that includes a mol. complex between urea and a functional substance that has at least one hydroxyl group and one carboxyl group either as a free acid, a salt, an amide or a lactone. The compns. are stable when compared to conventional urea-contg. compns., and provide controlled-release of the urea. For example, urea 15 g was dissolved in 27 mL water and galacturonic acid 8 g was slowly added to form a mol. complex until the soln. changed pH from 7.4 to 1.9. A clear soln. contg. the mol. complex was mixed with a hydrophilic ointment.

~2 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**16. Selective enzyme treatment of skin conditions**

By Fein, Howard

From U.S. Pat. Appl. Publ. (2005), US 20030026794 A1 20030206. Language: English, Database: CAPLUS

A method of **treating** skin conditions by providing compns. contg. enzymes to selectively remove specific layers of skin. The depth of skin removed (i.e., vertical surface **treated**) is regulated by the type and concn. of enzyme or enzymes in the compn. The surface area of skin removed (i.e., radial surface **treated**) is regulated by the area of topical application. Conditions **treatable** by the method include, but are not limited to, age-related conditions such as lines and **wrinkles**, infections, pigmentary disorders, follicular disorders such as acne, and hyperkeratotic disorders such as warts. The method and compn. of the invention thus achieves the specificity and efficacy of more invasive methods such as surgery, while providing a compn. that may be topically applied and is easy to use.

~1 Citing

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

**17. Pharmaceutical and cosmetic compositions containing oligosaccharide aldonic acids and their topical use**

By Yu, Ruey J.; Van Scott, Eugene J.

From PCT Int. Appl. (2001), WO 2001001932 A2 20010111. Language: English, Database: CAPLUS

Compns. comprising oligosaccharide aldonic acids are useful for general care, as well as for **treatment** and prevention, of various cosmetic conditions and dermatol. disorders, including those assocd. with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as **treatment** and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as **treatment** and prevention of oral and gum diseases; and for wound healing of the skin. Compns. comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects. A cream was prepd. by mixing 50 g of 50% maltobionic acid with 50 g oil-in-water base, pH = 1.7. Efficacy of topical maltobionic acid in **treatment** of dry skin is reported.

~11 Citings

0 Tags

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.

18. **Therapeutic Hotline: Facial skin rejuvenation in a patient treated with photodynamic therapy for actinic keratosis**

By Bruscolo Nicola; Fossi Riccardo; Dindelli Margherita; Gherseich Ilaria; Lotti Torello

From Dermatologic therapy (2010), 29(1), 85-9. Language: English, Database: MEDLINE

The aim of the most used **treatments** of actinic keratoses (AKs) is to avoid the conversion into invasive squamous cell carcinoma through the destruction of the lesion; a lot of therapeutic modalities (**imiquimod**, 5-fluorouracil, electrosurgery with curettage, cryosurgery) are effective and safe in this field, but not many can do it with excellent cosmetic results like **treatment** with photodynamic therapy (PDT). We have **treated** with this technique an old patient, whose AK was resistant to other **treatments**; the most interesting feature of our case comes from the esthetic effects of the PDT employing a methyl-ester of 5-aminolevulinic acid as topical photosensitizer. This kind of therapy has removed not only the lesion but also the photoaging manifestations like the **wrinkles** and the ugly lines, leaving a smooth skin, as we have proved with 3D-profilometry technique.

~0 Citings

0 Tags

0 Comments

Copyright © 2011 U.S. National Library of Medicine.